Could a common diabetes drug help fight a rare lung disease?
NCT ID NCT07520110
First seen Apr 10, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This study tests whether metformin, a standard diabetes medicine, can slow breathing problems in people with idiopathic pulmonary fibrosis (IPF), a serious lung disease. About 400 high-risk participants will receive either metformin or a placebo, and researchers will track who lives longer, avoids hospital stays, or needs a lung transplant. The goal is to find a new way to manage IPF and improve outcomes for those most at risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Massachusetts Chan Medical School
Worcester, Massachusetts, 01655, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.